Covered recipient · General Payments record
PEARL CHU KWONG
Allopathic & Osteopathic Physicians Dermatology Pediatric Dermatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$748,092.92
639 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $399,208.90 | 105 |
| Consulting Fee | $153,924.00 | 38 |
| Travel and Lodging | $83,277.40 | 183 |
| Honoraria | $82,375.00 | 23 |
| Food and Beverage | $14,670.87 | 286 |
| Compensation for serving as faculty or as a speaker for a medical education program | $14,520.00 | 3 |
| Gift | $116.75 | 1 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Arcutis Biotherapeutics, Inc. | $109,566.96 | 96 |
| GENZYME CORPORATION | $104,851.94 | 47 |
| Regeneron Healthcare Solutions, Inc. | $101,996.97 | 73 |
| Lilly USA, LLC | $87,651.82 | 69 |
| Organon LLC | $86,013.07 | 67 |
| PFIZER INC. | $63,394.71 | 48 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $37,151.53 | 38 |
| ABBVIE INC. | $36,318.86 | 31 |
| Incyte Corporation | $35,950.43 | 48 |
| Botanix SB Inc | $29,431.83 | 21 |
| Galderma Laboratories, L.P. | $14,303.71 | 32 |
| LEO Pharma Inc. | $12,005.73 | 17 |
| LNHC, Inc | $11,184.55 | 12 |
| Verrica Pharmaceuticals Inc. | $7,407.12 | 9 |
| Takeda Pharmaceuticals U.S.A., Inc. | $5,276.00 | 2 |
| Amgen Inc. | $2,795.19 | 11 |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $1,590.07 | 7 |
| Kowa Pharmaceuticals America, Inc. | $750.00 | 1 |
| Journey Medical Corporation | $151.88 | 2 |
| Novartis Pharmaceuticals Corporation | $86.98 | 2 |
| Almirall LLC | $76.19 | 3 |
| Regeneron Pharmaceuticals, Inc. | $72.30 | 1 |
| E.R. Squibb & Sons, L.L.C. | $35.13 | 1 |
| Eli Lilly and Company | $29.95 | 1 |
Page 4 of 13; records 151–200 of 639 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
PEARL CHU KWONG
NPI 1043309909 · CMS profile ID 620680
Allopathic & Osteopathic Physicians / Dermatology / Pediatric Dermatology
JACKSONVILLE, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 4 of 13; records 151–200 of 639 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1043309909?year=2025&recipient=provider&page=4#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- PEARL CHU KWONG, NPI 1043309909, CMS profile ID 620680. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 13; records 151–200 of 639 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1043309909?year=2025&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). PEARL CHU KWONG, NPI 1043309909, CMS profile ID 620680. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 13; records 151–200 of 639 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1043309909?year=2025&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- PEARL CHU KWONG, NPI 1043309909, CMS profile ID 620680, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 13; records 151–200 of 639 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1043309909?year=2025&recipient=provider&page=4#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
639 matching records · $748,092.92 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 151–200 of 639.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| PFIZER INC. | $5,250.00 | 08/19/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1229438435 | CMS |
| PFIZER INC. | $89.78 | 08/19/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1229452637 | CMS |
| PFIZER INC. | $281.30 | 08/19/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1229500553 | CMS |
| PFIZER INC. | $79.80 | 08/19/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1229505734 | CMS |
| PFIZER INC. | $79.80 | 08/19/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1230101666 | CMS |
| Arcutis Biotherapeutics, Inc. | $348.11 | 08/18/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1252365853 | CMS |
| Arcutis Biotherapeutics, Inc. | $2,250.00 | 08/18/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1252365855 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $17.32 | 08/18/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1251045390 | CMS |
| Lilly USA, LLC | $821.83 | 08/14/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186790751 | CMS |
| Lilly USA, LLC | $695.25 | 08/14/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186816327 | CMS |
| Lilly USA, LLC | $186.67 | 08/14/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186840165 | CMS |
| Organon LLC | $4,800.00 | 08/14/2025 | Honoraria | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1237642578 | CMS |
| Organon LLC | $4,800.00 | 08/14/2025 | Honoraria | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1237642580 | CMS |
| Regeneron Healthcare Solutions, Inc. | $29.88 | 08/14/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1212968223 | CMS |
| Galderma Laboratories, L.P. | $134.63 | 08/13/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234667557 | CMS |
| LNHC, Inc | $5,200.00 | 08/13/2025 | Honoraria | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1242603322 | CMS |
| Organon LLC | $107.00 | 08/12/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1237642514 | CMS |
| Organon LLC | $475.36 | 08/12/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1237642530 | CMS |
| Organon LLC | $494.94 | 08/12/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1237642532 | CMS |
| Organon LLC | $752.76 | 08/12/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1237642538 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $19.02 | 08/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1220086248 | CMS |
| LNHC, Inc | $413.97 | 08/09/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1242603306 | CMS |
| LNHC, Inc | $207.28 | 08/09/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1242603308 | CMS |
| LNHC, Inc | $160.85 | 08/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1242603310 | CMS |
| LNHC, Inc | $65.00 | 08/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1242603312 | CMS |
| LNHC, Inc | $80.00 | 08/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1242603314 | CMS |
| LNHC, Inc | $45.00 | 08/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1242603316 | CMS |
| LNHC, Inc | $36.84 | 08/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1242603318 | CMS |
| LNHC, Inc | $116.75 | 08/09/2025 | Gift | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1242603320 | CMS |
| Incyte Corporation | $4,500.00 | 08/08/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225961547 | CMS |
| Incyte Corporation | $4,875.00 | 08/08/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226140811 | CMS |
| PFIZER INC. | $4,125.00 | 08/08/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1229216626 | CMS |
| ABBVIE INC. | $125.04 | 08/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1202252371 | CMS |
| ABBVIE INC. | $938.93 | 08/07/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1202252373 | CMS |
| Arcutis Biotherapeutics, Inc. | $11.25 | 08/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1252365841 | CMS |
| PFIZER INC. | $91.35 | 08/07/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1229410063 | CMS |
| PFIZER INC. | $91.34 | 08/07/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1229442744 | CMS |
| PFIZER INC. | $12.33 | 08/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1229148381 | CMS |
| PFIZER INC. | $112.39 | 08/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1230030389 | CMS |
| Organon LLC | $75.92 | 08/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1237642502 | CMS |
| Organon LLC | $132.09 | 08/05/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1237642520 | CMS |
| Organon LLC | $2,086.00 | 08/05/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1237642564 | CMS |
| ABBVIE INC. | $21.90 | 08/04/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1202252369 | CMS |
| PFIZER INC. | $3,425.00 | 08/04/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1229006176 | CMS |
| Arcutis Biotherapeutics, Inc. | $235.84 | 07/30/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1252365993 | CMS |
| Amgen Inc. | $123.78 | 07/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228351638 | CMS |
| Arcutis Biotherapeutics, Inc. | $51.04 | 07/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1252365839 | CMS |
| Regeneron Healthcare Solutions, Inc. | $1,495.00 | 07/25/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1212968221 | CMS |
| Verrica Pharmaceuticals Inc. | $37.43 | 07/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1222326922 | CMS |
| Arcutis Biotherapeutics, Inc. | $6,375.00 | 07/24/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1252365917 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $499,626.02 | 53 |
| PY2024 | Recipient | $4,483.58 | 2 |
| PY2024 | Principal investigator | $379,733.67 | 321 |
| PY2023 | Principal investigator | $482,886.26 | 183 |
| PY2022 | Recipient | $25,287.00 | 4 |
| PY2022 | Principal investigator | $560,681.04 | 47 |
| PY2021 | Recipient | $4,616.73 | 4 |
| PY2021 | Principal investigator | $1,046,532.75 | 41 |
| PY2020 | Recipient | $2,327.84 | 4 |
| PY2020 | Principal investigator | $968,139.38 | 80 |
| PY2019 | Recipient | $18,487.26 | 3 |
| PY2019 | Principal investigator | $846,211.79 | 54 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
53 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | PFIZER INC. | $15,500.00 | 12/31/2025 | Non-covered Recipient Entity Suncoast Holdings Target LLC | A PHASE 3 MULTICENTER LONGTERM OPEN LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO PEDIATRIC PARTICIPANTS AGED 2 YEARS AND OLDER WITH MODERATETOSEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228736727 |
| Principal investigator 1 | PFIZER INC. | $3,405.82 | 12/31/2025 | Non-covered Recipient Entity Suncoast Holdings Target LLC | PHASE 1 PKPD STUDY 6 TO 12 A STUDY TO DETERMINE THE SAFETY AND TOLERABILITY OF JAK1 IN PATIENTS AGED 6 TO 12 | No dispute reported | 06/30/2026 | 1228745259 |
| Principal investigator 1 | PFIZER INC. | $2,500.00 | 12/16/2025 | Non-covered Recipient Entity Suncoast Skin Solutions LLC | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228738886 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $14,500.00 | 12/11/2025 | Non-covered Recipient Entity Apex Clinical Research Center LLC | Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1252796996 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $17,239.00 | 12/10/2025 | Non-covered Recipient Entity Suncoast Holdings Target Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment | No dispute reported | 06/30/2026 | 1226103935 |
| Principal investigator 1 | ABBVIE INC. | $1,470.20 | 12/04/2025 | Non-covered Recipient Entity SOLUTIONS THROUGH ADVANCED RESEARCH | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 | No dispute reported | 06/30/2026 | 1202526794 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $37,293.00 | 12/04/2025 | Non-covered Recipient Entity Suncoast Holdings Target Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment | No dispute reported | 06/30/2026 | 1226103909 |
| Principal investigator 1 | Eli Lilly and Company | $9,436.00 | 11/25/2025 | Non-covered Recipient Entity APEX RESEARCH FOUNDATION LLC | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | No dispute reported | 06/30/2026 | 1187880713 |
| Principal investigator 1 | PFIZER INC. | $1,736.48 | 11/25/2025 | Non-covered Recipient Entity Suncoast Holdings Target LLC | PHASE 1 PKPD STUDY 6 TO 12 A STUDY TO DETERMINE THE SAFETY AND TOLERABILITY OF JAK1 IN PATIENTS AGED 6 TO 12 | No dispute reported | 06/30/2026 | 1228737576 |
| Principal investigator 1 | Eli Lilly and Company | $15,500.00 | 11/24/2025 | Non-covered Recipient Entity APEX CLINICAL TRIALS LLC SUNCOAST HOLDINGS TARGET LLC | A PHASE 4, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH ATOPIC DERMATITIS WITH LIMITED BODY SURFACE AREA INVOLVEMENT AND HIGH ITCH BURDEN (ADSOLVE) | No dispute reported | 06/30/2026 | 1187876257 |
| Principal investigator 1 | PFIZER INC. | $450.00 | 11/19/2025 | Non-covered Recipient Entity APEX Clinical Trials | PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY | No dispute reported | 06/30/2026 | 1228739443 |
| Principal investigator 1 | PFIZER INC. | $3,714.07 | 11/18/2025 | Non-covered Recipient Entity Suncoast Holdings Target LLC | PHASE 1 PKPD STUDY 6 TO 12 A STUDY TO DETERMINE THE SAFETY AND TOLERABILITY OF JAK1 IN PATIENTS AGED 6 TO 12 | No dispute reported | 06/30/2026 | 1228727205 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $9,744.00 | 10/17/2025 | Non-covered Recipient Entity Suncoast Holdings Target Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment | No dispute reported | 06/30/2026 | 1226103858 |
| Principal investigator 1 | ABBVIE INC. | $2,940.40 | 10/09/2025 | Non-covered Recipient Entity SOLUTIONS THROUGH ADVANCED RESEARCH | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 | No dispute reported | 06/30/2026 | 1202513853 |
| Principal investigator 1 | Arcutis Biotherapeutics, Inc. | $3,623.65 | 09/26/2025 | Non-covered Recipient Entity Suncoast Holding Target LLC | A Phase 2, Open Label, 4-Week, Safety Study of RoflumilastCream 0.05% Administered Once Daily in Infants Aged 3Months to Less Than 2 Years with AtopicDermatitis | No dispute reported | 06/30/2026 | 1248163808 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $14,003.00 | 09/17/2025 | Non-covered Recipient Entity Suncoast Holdings Target Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment | No dispute reported | 06/30/2026 | 1226103821 |
| Principal investigator 1 | Eli Lilly and Company | $2,945.86 | 09/09/2025 | Non-covered Recipient Entity SOLUTIONS THROUGH ADVANCED RESEARCH | A PHASE 4, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH ATOPIC DERMATITIS WITH LIMITED BODY SURFACE AREA INVOLVEMENT AND HIGH ITCH BURDEN (ADSOLVE) | No dispute reported | 06/30/2026 | 1187888518 |
| Principal investigator 1 | PFIZER INC. | $6,500.00 | 09/08/2025 | Non-covered Recipient Entity APEX Clinical Trials | PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY | No dispute reported | 06/30/2026 | 1228714180 |
| Principal investigator 1 | ABBVIE INC. | $3,356.20 | 09/03/2025 | Non-covered Recipient Entity SOLUTIONS THROUGH ADVANCED RESEARCH | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 | No dispute reported | 06/30/2026 | 1202508178 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $35,092.00 | 08/20/2025 | Non-covered Recipient Entity Suncoast Holdings Target Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment | No dispute reported | 06/30/2026 | 1226103791 |
| Principal investigator 1 | PFIZER INC. | $450.00 | 08/11/2025 | Non-covered Recipient Entity APEX Clinical Trials | PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY | No dispute reported | 06/30/2026 | 1228714252 |
| Principal investigator 1 | Arcutis Biotherapeutics, Inc. | $3,418.15 | 08/07/2025 | Non-covered Recipient Entity Suncoast Holding Target LLC | A Phase 2, Open Label, 4-Week, Safety Study of RoflumilastCream 0.05% Administered Once Daily in Infants Aged 3Months to Less Than 2 Years with AtopicDermatitis | No dispute reported | 06/30/2026 | 1248163806 |
| Principal investigator 1 | ABBVIE INC. | $1,678.10 | 08/05/2025 | Non-covered Recipient Entity SOLUTIONS THROUGH ADVANCED RESEARCH | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 | No dispute reported | 06/30/2026 | 1202501640 |
| Principal investigator 1 | PFIZER INC. | $1,447.00 | 07/16/2025 | Non-covered Recipient Entity APEX Clinical Trials | PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY | No dispute reported | 06/30/2026 | 1228714178 |
| Principal investigator 1 | PFIZER INC. | $15,500.00 | 07/11/2025 | Non-covered Recipient Entity Suncoast Holdings Target LLC | PHASE 1 PKPD STUDY 6 TO 12 A STUDY TO DETERMINE THE SAFETY AND TOLERABILITY OF JAK1 IN PATIENTS AGED 6 TO 12 | No dispute reported | 06/30/2026 | 1228782687 |
| Principal investigator 1 | ABBVIE INC. | $1,678.10 | 07/02/2025 | Non-covered Recipient Entity SOLUTIONS THROUGH ADVANCED RESEARCH | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 | No dispute reported | 06/30/2026 | 1202495615 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $19,950.00 | 06/27/2025 | Non-covered Recipient Entity Suncoast Holdings Target Llc | A Multicenter Open-label Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants >=6 Months to <18 Years of Age With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1226103724 |
| Principal investigator 1 | Incyte Corporation | $10,000.00 | 06/05/2025 | Non-covered Recipient Entity SOLUTIONS THROUGH ADVANCED RESEARCH, INC | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240591735 |
| Principal investigator 1 | Incyte Corporation | $2,500.00 | 06/05/2025 | Non-covered Recipient Entity SOLUTIONS THROUGH ADVANCED RESEARCH, INC | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240591738 |
| Principal investigator 1 | ABBVIE INC. | $5,928.43 | 06/03/2025 | Non-covered Recipient Entity SOLUTIONS THROUGH ADVANCED RESEARCH | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202488443 |
| Principal investigator 1 | ABBVIE INC. | $2,940.40 | 06/03/2025 | Non-covered Recipient Entity SOLUTIONS THROUGH ADVANCED RESEARCH | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 | No dispute reported | 06/30/2026 | 1202488445 |
| Principal investigator 1 | PFIZER INC. | $2,695.00 | 05/30/2025 | Non-covered Recipient Entity Suncoast Skin Solutions LLC | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228771840 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $19,950.00 | 05/12/2025 | Non-covered Recipient Entity Suncoast Holdings Target Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment | No dispute reported | 06/30/2026 | 1226103712 |
| Principal investigator 1 | Arcutis Biotherapeutics, Inc. | $8,500.00 | 05/09/2025 | Non-covered Recipient Entity Suncoast Holding Target LLC | A Phase 2, Open Label, 4-Week, Safety Study of RoflumilastCream 0.05% Administered Once Daily in Infants Aged 3Months to Less Than 2 Years with AtopicDermatitis | No dispute reported | 06/30/2026 | 1248163804 |
| Principal investigator 1 | ABBVIE INC. | $3,697.75 | 05/07/2025 | Non-covered Recipient Entity SOLUTIONS THROUGH ADVANCED RESEARCH | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202483427 |
| Principal investigator 1 | ABBVIE INC. | $2,940.40 | 05/06/2025 | Non-covered Recipient Entity SOLUTIONS THROUGH ADVANCED RESEARCH | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 | No dispute reported | 06/30/2026 | 1202481845 |
| Principal investigator 1 | Eli Lilly and Company | $1,876.40 | 04/22/2025 | Non-covered Recipient Entity SOLUTIONS THROUGH ADVANCED RESEARCH | AN OPEN-LABEL, 24-WEEK STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS AND SKIN OF COLOR | No dispute reported | 06/30/2026 | 1187888874 |
| Principal investigator 1 | Eli Lilly and Company | $55,305.00 | 04/15/2025 | Non-covered Recipient Entity APEX CLINICAL TRIALS LLC SUNCOAST HOLDINGS TARGET LLC | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | No dispute reported | 06/30/2026 | 1187876035 |
| Principal investigator 1 | Eli Lilly and Company | $15,933.60 | 04/10/2025 | Non-covered Recipient Entity SOLUTIONS THROUGH ADVANCED RESEARCH | A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1187890884 |
| Principal investigator 1 | ABBVIE INC. | $1,678.10 | 04/03/2025 | Non-covered Recipient Entity SOLUTIONS THROUGH ADVANCED RESEARCH | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 | No dispute reported | 06/30/2026 | 1202471409 |
| Principal investigator 1 | Eli Lilly and Company | $2,417.83 | 03/25/2025 | Non-covered Recipient Entity SOLUTIONS THROUGH ADVANCED RESEARCH | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | No dispute reported | 06/30/2026 | 1187890958 |
| Principal investigator 1 | ABBVIE INC. | $1,678.10 | 03/06/2025 | Non-covered Recipient Entity SOLUTIONS THROUGH ADVANCED RESEARCH | M19-973 - Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 | No dispute reported | 06/30/2026 | 1202457593 |
| Principal investigator 1 | UCB SA | $12,101.40 | 03/03/2025 | Non-covered Recipient Entity SOLUTIONS THROUGH ADVANCED RESEARCH INC | MULTICENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, PLACEBO-CONTROLLED (12 17 YEARS) INCLUDING A SINGLE OPEN LABEL ARM (6 11 YEARS) STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF CERTOLIZUMAB PEGOL (CZP) IN PEDIATRIC STUDY PARTICIPANTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS (PSO) | No dispute reported | 06/30/2026 | 1246656380 |
| Principal investigator 1 | Incyte Corporation | $10.00 | 02/25/2025 | Non-covered Recipient Entity SOLUTIONS THROUGH ADVANCED RESEARCH, INC | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240591742 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $87.34 | 02/19/2025 | Non-covered Recipient Entity SUNCOAST SKIN SOLUTIONS | Pediatric Study in children with moderate to severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1190303351 |
| Principal investigator 1 | PFIZER INC. | $1,447.00 | 02/14/2025 | Non-covered Recipient Entity APEX Clinical Trials | PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY | No dispute reported | 06/30/2026 | 1228714176 |
| Principal investigator 1 | Eli Lilly and Company | $5,948.51 | 02/10/2025 | Non-covered Recipient Entity SOLUTIONS THROUGH ADVANCED RESEARCH | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1187888876 |
| Principal investigator 1 | ABBVIE INC. | $3,356.20 | 02/05/2025 | Non-covered Recipient Entity SOLUTIONS THROUGH ADVANCED RESEARCH | M19-973 - Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 | No dispute reported | 06/30/2026 | 1202444955 |
| Principal investigator 1 | Eli Lilly and Company | $1,940.79 | 01/27/2025 | Non-covered Recipient Entity SOLUTIONS THROUGH ADVANCED RESEARCH | A PHASE 3, MULTICENTER, LONG-TERM EXTENSION STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PARTICIPANTS 6 MONTHS TO <18 YEARS OF AGE WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1187890956 |
| Principal investigator 1 | Eli Lilly and Company | $47,037.00 | 01/21/2025 | Non-covered Recipient Entity SOLUTIONS THROUGH ADVANCED RESEARCH | A PHASE 3, MULTICENTER, LONG-TERM EXTENSION STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PARTICIPANTS 6 MONTHS TO <18 YEARS OF AGE WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1187890656 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,785.60 | 01/14/2025 | Non-covered Recipient Entity SOLUTION THROUGH ADVANCED RESEARCH INC | Pediatric Study in children with moderate to severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1190309736 |
| Principal investigator 1 | Eli Lilly and Company | $39,859.74 | 01/07/2025 | Non-covered Recipient Entity SOLUTIONS THROUGH ADVANCED RESEARCH | A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS (PK) OF BARICITINIB IN CHILDREN FROM 6 YEARS TO LESS THAN 18 YEARS OF AGE WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1187890886 |
| Principal investigator 1 | ABBVIE INC. | $2,940.40 | 01/02/2025 | Non-covered Recipient Entity SOLUTIONS THROUGH ADVANCED RESEARCH | M19-973 - Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 | No dispute reported | 06/30/2026 | 1202434726 |